Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
ACE Reports.
Osteoarthritis
A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients.
Clin Exp Rheumatol. 2025 01-May;():. 10.55563/clinexprheumatol/gskbin
A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients.
Clin Exp Rheumatol. 2025 01-May;():. 10.55563/clinexprheumatol/gskbin
Osteoarthritis
Omeract-oarsi ‘strict responders’ analysis from results of a randomized, double-blind, placebo-controlled phase 1 study of a novel, intra-articular, injectable, wnt inhibitor (sm04690) in the treatment of osteoarthritis of the knee
Omeract-oarsi ‘strict responders’ analysis from results of a randomized, double-blind, placebo-controlled phase 1 study of a novel, intra-articular, injectable, wnt inhibitor (sm04690) in the treatment of osteoarthritis of the knee